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Summary
Frangakis and Rubin (2002, Biometrics 58, 21–29) proposed a new definition of a surrogate endpoint
(a “principal” surrogate) based on causal effects. We introduce an estimand for evaluating a principal
surrogate, the causal effect predictiveness (CEP) surface, which quantifies how well causal treatment
effects on the biomarker predict causal treatment effects on the clinical endpoint. Although the CEP
surface is not identifiable due to missing potential outcomes, it can be identified by incorporating a
baseline covariate(s) that predicts the biomarker. Given case–cohort sampling of such a baseline
predictor and the biomarker in a large blinded randomized clinical trial, we develop an estimated
likelihood method for estimating the CEP surface. This estimation assesses the “surrogate value” of
the biomarker for reliably predicting clinical treatment effects for the same or similar setting as the
trial. A CEP surface plot provides a way to compare the surrogate value of multiple biomarkers. The
approach is illustrated by the problem of assessing an immune response to a vaccine as a surrogate
endpoint for infection.
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1. Introduction
Identifying biomarkers that can be used as approximate surrogates for clinical endpoints in
randomized trials is useful for many reasons including shortening studies, reducing costs,
sparing study participants discomfort, and elucidating treatment effect mechanisms. As a
motivating example, a central objective of placebo-controlled preventive HIV vaccine efficacy
trials is the evaluation of vaccine-induced immune responses as surrogate endpoints for HIV
infection. An immunological surrogate would be useful for several purposes including guiding
iterative development of immunogens between basic and clinical research, informing
regulatory decisions and immunization policies, and bridging efficacy of a vaccine observed
in a trial to a new setting.
The surrogate evaluation field was catalyzed by Prentice’s (1989) definition of a surrogate
endpoint as a replacement endpoint that provides a valid test of the null hypothesis of no
treatment effect on the clinical endpoint. The two main criteria for checking this definition are:
(i) the distribution of the clinical endpoint conditional on the surrogate is the same as the
distribution of the clinical endpoint conditional on the surrogate and treatment (i.e., all of the
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clinical treatment effect is “mediated” through the surrogate); and (ii) the surrogate and clinical
endpoints are correlated. Frangakis and Rubin (2002) (henceforth FR) noted that this definition
is based on observable random variables, and named a biomarker satisfying criterion (i) a
“statistical surrogate.” Since 1989, many surrogate-evaluation methods have been designed to
check if a biomarker is a statistical surrogate, including methods for estimating the proportion
of the treatment effect explained (Freedman, Graubard, and Schatzkin, 1992). Notably some
approaches have not been based on (i); for example, the adjusted association estimand is
designed for evaluating the correlation criterion (ii), and the relative effect estimand is based
on average causal effects (Buyse and Molenberghs, 1998).
Treatment effects adjusted for a variable measured after randomization (called net effects) are
susceptible to postran-domization selection bias. Because candidate surrogates are measured
after randomization, criterion (i) defining a statistical surrogate is based on net effects. FR
pointed out that this definition does not have a causal interpretation, and proposed a new
surrogate definition based on principal causal effects. FR’s definition of a “principal surrogate”
is based on the potential outcomes framework for causal inference, which Robins (1995) also
considered for studying treatment effects subject to postrandomization selection bias. To date,
statistical methods for evaluating principal surrogates have not been elaborated. A recent
review paper noted that FR “present a convincing case for the principal surrogate definition”
and called for such elaborations (Weir and Walley, 2006).
The literature on statistical methods for evaluating surrogate endpoints contains approaches
based on a single large clinical trial and on metaanalysis. Here we develop an approach for
evaluating a principal surrogate within the former setting. Following Follmann (2006), our
approach uses a baseline covariate(s) to predict missing potential biomarker outcomes. After
defining statistical and principal surrogates in Section 2, in Section 3 we introduce the causal
effect predictiveness (CEP) surface and the marginal CEP curve, plus associated summary
causal estimands, which quantify how well a biomarker predicts population-level causal effects
of treatment. In Section 4, we develop an estimated-likelihood approach for estimating the
causal estimands based on case–cohort sampling of the biomarker, and parametric or
nonparametric marginal structural mean models. In Section 5, we evaluate the nonparametric
method in simulations based on an HIV vaccine trial, and in Section 6 we conclude with
discussion.
2. Statistical and Principal Surrogates
Throughout we consider a randomized trial with treatment assignment Z (Z = 1 or 0), a discrete
or continuous biomarker S measured at fixed time t0 after treatment assignment, and a binary
clinical endpoint Y (Y = 1 for disease, 0 otherwise) measured after t0. Because S must be
measured prior to disease to evaluate it as a candidate surrogate, the analysis is restricted to
subjects disease free at t0; denote this evaluability criterion by the indicator V = 1. The
biomarker S is only measured in those with V = 1, and otherwise is undefined (denoted by S =
*). We consider two phase outcome-dependent case–cohort sampling, wherein baseline
covariates X are measured for everyone (phase 1) and in the second phase a baseline covariate
(s) W is measured for all or almost all cases (those with Y = 1) and for a random “subcohort”
of controls (those with Y = 0). Let δ indicate whether W is measured. For subjects with V = 1,
S is measured for those with W measured. Case–cohort sampling is efficient when W or S is
expensive (Prentice, 1986). For vaccine trials, W and S can be measured after the trial using
stored specimens (Gilbert et al., 2005).
2.1 Definition of a Statistical Surrogate
Following FR, methods for evaluating statistical surrogates are based on comparing the risk
distributions
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If S is continuous then these definitions abuse notation; however, to avoid the distraction of
technical details the formal definitions are placed in Web Appendix A. FR defined S to be a
statistical surrogate if, for all values s of S, risk(s | Z = 1) = risk(s | Z = 0).
Because S and V are measured after randomization, a comparison of risk(s | Z = 1) and risk(s
| Z = 0) measures the net effect of treatment, i.e., differences due to a mixture of the causal
treatment effect and any differences in characteristics between treatment 1 subjects who have
response level s, {Z = 1, V = 1, S = s}, and treatment 0 subjects who have response level s,
{Z = 0, V = 1, S = s}. Consequently, application of a method that evaluates a statistical surrogate
may mislead about the capacity of a biomarker to reliably predict causal clinical treatment
effects.
2.2 Definition of a Principal Surrogate Endpoint
Let Y(Z) be the potential clinical endpoint after time t0 under assignment to treatment Z.
Similarly define potential outcomes S(Z) for the biomarker endpoint measured at t0, and let V
(Z) be the potential indicators of whether the subject is disease free at t0, for Z = 0,1. Note that
S(Z) and Y(Z) are undefined if V(Z) = 0; in this case S(Z) = Y(Z) = *. We suppose that (Zi, Xi,
δi, δiWi, V i(1), V i(0), Si(1), Si(0), Y i(1), Y i(0)), i = 1,…, n, are independent and identically
distributed (i.i.d.), and for simplicity assume no drop-out. Further we assume A1–A3:
ASSUMPTION A1—Stable unit treatment value assumption (SUTVA)
ASSUMPTION A2—Ignorable treatment assignments (Rubin, 1986): Conditional on X, Z is
independent of (W, V (1), V (0), S(1), S(0), Y (1), Y(0))
ASSUMPTION A3—Equal individual clinical risk up to time t0 : V(1) = 1 if and only if V
(0) = 1
A1 implies that the potential outcomes (V i(1), V i(0), Si(1), Si(0), Y i(1), Y i(0)) are independent
of the treatment assignments of other subjects, which implies “consistency,” (V i(Zi), Si(Zi),
Y i(Zi)) = (V i, Si, Y i). A2 holds for blinded randomized trials, where the randomization may
depend on X. A3 will be needed for identifying the causal estimand based on data from subjects
observed to be at risk for disease at t0. Inferences will be robust to A3 if t0 is near baseline
relative to the period of follow-up for clinical events and the vast majority of subjects are at
risk at t0, in which case V i(1) = V i(0) = 1 for almost all i.
With these preliminaries, we now define a principal surrogate endpoint. FR defined the basic
principal stratification P0 with respect to the postrandomization variable S as the partition of
units i = 1, … , n such that within any set of P0, all units have the same vector (Si(1), Si(0)). A
principal stratification is a partition of units whose sets are unions of sets in P0. FR defined a
biomarker S to be a principal surrogate endpoint if the comparison between
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results in equality for all s1 = s0. FR did not explicitly condition on V (1) = V (0) = 1 in their
definition; however, implicitly they must have, because (S(1), S(0)) is only defined if V (1) =
V (0) = 1. For notational simplicity henceforth all probability statements involving S(Z)
implicitly condition on V (Z) = 1. A contrast in risk(1)(s1, s0) and risk(0)(s1, s0) measures a
population-level causal treatment effect on Y for subjects with {Si(1) = s1, Si(0) = s0}. Such a
contrast is causal because it conditions on a principal stratification, which, by construction, is
unaffected by treatment. Thus in FR’s definition, S is a principal surrogate if groups of subjects
with no causal effect on the biomarker have no causal effect on the clinical endpoint. We call
this property average causal necessity.
Average causal necessity—risk(1)(s1, s0) = risk(0)(s1, s0) for all s1 = s0.
Biomarkers with the greatest utility for predicting clinical treatment effects will not only be
necessary for a clinical effect, but also sufficient. For example, knowing that an antibody titer
> 1000 is sufficient for a vaccine to protect individuals against HIV infection is exactly the
information needed to use titer as a reliable predictor of protection. We define average causal
sufficiency as
Average causal sufficiency—There exists a constant C ≥ 0 such that risk(1)(s1, s0) ≠
risk(0)(s1, s0) for all |s1 − s0| > C.
For the one-sided situation where interest is in assessing if higher treatment 1 biomarker
responses (S(1) > S(0)) predict clinical benefit of treatment 1 (Y (1) = 0 and Y (0) = 1) (e.g., a
placebo-controlled trial), a one-sided version of average causal sufficiency may be more
appropriate, defined as above with ≠ replaced with < and |s1 − s0| replaced with s1 − s0. In
either case, we suggest a refined definition of a principal surrogate endpoint as a biomarker
that satisfies both average causal necessity and average causal sufficiency. Henceforth we use
this definition of a principal surrogate endpoint.
3. Causal Effect Predictiveness Estimands
3.1 Quantitation of Associative and Dissociative Effects
FR suggested that the quality of a surrogate be measured by its “associative effects” relative
to its “dissociative effects.” As defined in equation 5.3 and of FR, an associative effect is a
comparison between the ordered sets
and a dissociative effect is a comparison between the ordered sets
For the purpose of quantifying these effects, we introduce a causal effect predictiveness (CEP)
surface. Let CE ≡ h(Pr(Y (1) = 1), Pr(Y (0) = 1)) be the overall causal effect of treatment on
the clinical endpoint, where h(·, ·) is a known contrast function satisfying h(x, y)= 0 if and only
if x = y, for example h(x, y) = x − y or log(x/y). Let
be this contrast conditional on {S(1) = s1, S(0) = s0}. Note that CEPrisk(s, s) = 0 for all s is
equivalent to average causal necessity, whereas CEPrisk(s1, s0) ≠ 0 for all |s1 − s0| > C (or the
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one-sided analog) is equivalent to average causal sufficiency. Therefore, the criteria for a
principal surrogate can be checked through inference on the CEP surface. Moreover,
biomarkers with capacity to predict clinical treatment effects will often have |CEPrisk(s1, s0)|
increasing in |s1 − s0|, reflecting the situation that on average groups of persons with a greater
causal effect on the marker have a greater causal effect on the clinical endpoint. We refer to
the capacity of a biomarker to reliably predict the population level causal effect of treatment
on the clinical endpoint as the biomarkers’ surrogate value. This value can be quantified both
by the nearness of |CEPrisk(s1, s0)| to 0 for s1 near s0 and by the extent to which |CEPrisk(s1,
s0)| increases with |s1 − s0|, with a greater increase reflecting greater associative effects. Note
that even if one or both of average causal necessity or sufficiency fail, a biomarker can still
have surrogate value if |CEPrisk(s1, s0)| increases with |s1 − s0|; Figure 2 (dashed line) will
illustrate this. Moreover, two principal surrogates can have different surrogate values as
reflected by different CEP surfaces.
If S is continuous, then the CEP surface can alternatively be defined in terms of percentiles of
the marker S. To formulate this, consider Huang, Pepe, and Feng’s (2007) proposal to judge
the value of a continuous marker S for predicting disease Y by the predictiveness curve, R(υ)
≡ Pr(Y = 1| S = F−1(υ)), υ ∈ [0, 1], where F is the cumulative distributive function (cdf) of S.
Note that R(υ) = risk(S = F−1(υ)), i.e., R(υ) is risk as a function of the quantiles of S, which
provides a common scale for comparing multiple markers. The predictiveness curve R(υ)
usefully informs about both absolute risks at different marker quantiles and the frequency of
these risks in the population. A predictive marker is one with R(υ) monotone (or approximately
so) in υ with large |R(1) − R(0)|.
Applying these ideas, we propose a scale-independent version of the causal effect
predictiveness surface, CEPR(υ1, υ0) ≡ h(R(1)(υ1, υ0), R(0)(υ1, υ0)), where
In this definition, S(1) and S(0) are standardized relative to the distribution F(1) of S(1). Figure
1 illustrates two CEP surfaces for the one-sided setting where interest is in predicting clinical
benefit of treatment 1 from higher treatment 1 biomarker responses.
For some studies, the marginal CEP curve is a related causal estimand of interest:
where risk(Z)(s1) ≡ Pr(Y(Z) = 1| S(1) = s1). Similarly mCEPR(υ1) is defined as h(R(1)(υ1),
R(0)(υ1)) with . With h(x, y) = x − y, if S is continuous
and strictly increasing then the area between mCEPR(·) and the zero-line equals CE = Pr(Y (1)
= 1) − Pr(Y (0) = 1) (proof in Web Appendix A).
If Si(0) is constant across subjects, then the CEP surface (trivially) equals the marginal CEP
curve. We refer to this special case as case CB:
Case CB—Constant Biomarkers: Si(0) = c for all i for some constant c
HIV vaccine trials fit case CB, with (almost) all subjects having no immune response under
placebo (Z = 0). This occurs because S is an HIV-specific immune response, so that vaccine
antigens must be presented to the immune system to induce a response (Gilbert et al., 2005).
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The dissociative effect can be measured by CEPrisk(c, c) and the associative effects by
CEPrisk(s1, c) for s1 ≠ c. For example, with c = L the lower bound of S, the nearer CEPrisk(c,
c) is to zero and the greater the increase of |CEPrisk(s1, c)| with s1 > c, the greater the surrogate
value (Figure 2).
For placebo-controlled trials for which case CB fails yet Si(0) has much less variability than
Si(1), the marginal CEP curve has interpretation approximately equal to that of CEP(s1, s0). In
general, however, mCEP(s1) does not measure the association between causal biomarker
effects and causal clinical effects, and hence does not measure principal surrogate value.
Nevertheless, under A1 and A2 mCEP(s1) has a different but useful interpretation as the
population level causal treatment effect on Y for subjects with S(1) = s1, where conditioning
on S(1) is equivalent to conditioning on a baseline covariate. As such, the marginal CEP curve
can be used for predicting how clinical efficacy varies with the biomarker S = S(1) observed
in persons attending a treatment or vaccine clinic.
3.2 Estimands for Summarizing Surrogate Value
We suggest functionals of the CEP surface that summarize the surrogate value of a biomarker.
We again consider the one-sided setting where interest is in assessing whether S(1) > S(0)
predicts clinical benefit of treatment 1 (Y ( 1) = 0 and Y (0) = 1). To summarize the associative




where ω(·, ·) is a nonnegative weight function. For case CB with c = L, EAEω = {∫s1>c ω(s1,
c) dF(1)(s1)}−1 ∫s1>c × ω(s1, c)CEP
risk(s1, c) dF(1)(s1) and EDE = CEPrisk(c, c).
We also define the proportion associative (PA) effect by
(3)
Values of PAEω ∈ [0, 0.5] suggest the biomarker has no surrogate value, whereas values in
(0.5, 1] suggest some surrogate value.
A weight function is included in EAEω to reflect the idea that a biomarker with high surrogate
value should have large |CEPrisk(s1, s0)| for large s1 − s0 > 0. For example, weights ω(s1, s0)
= s1 − s0 or I(s1 = U, s0 = L) may be used, where L (U) is the lower (upper) bound of S. With
the latter weight, PAEω compares the clinical effect among groups with the maximum surrogate
effect and with no surrogate effect:
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If h(x, y) = x − y, Pr(S(1) > S(0)) = 0.5, and an additional monotonicity assumption is made
(that Y i(1) ≤ Y i(0) for all i, i.e., no one is harmed by treatment 1), then PAEω=1 equals the PA,
defined by
(proof in Web Appendix A). This summary measure, proposed by Taylor, Wang, and Thiebaut
(2005), is interpreted as the proportion of the study population with a beneficial causal clinical
effect that also has a positive causal surrogate effect. The PA depends on the underlying
principal strata distribution F(1),(0)(s1, s0) ≡ Pr(S(1) ≤ s1, S(0) ≤ s0); if Pr(S(1) > S(0)) is small
(large) then the PA will tend to be small (large), irrespective of the biomarker’s surrogate value.
By conditioning on (S(1), S(0)), the PAEω is designed to be robust to F(1),(0)(·, ·); the PAEω
reflects the relative magnitude of clinical effects for those with and without surrogate effects.
Biomarkers satisfying average causal necessity have EDE = 0 and thus PAEω = 1, in which
case EAEω contributes no information to the PAEω. Therefore, additional measures are needed
for summarizing the magnitude of associative effects. One such measure is the associative span
(AS), defined by AS ≡ |CEPrisk(U, L)| − |EDE|. Figure 2 illustrates PAEω=1 and AS. Although
the summary parameters may be useful, it is important to estimate the CEP estimands over the
range of marker values or quantiles to provide a full picture of the associative and dissociative
effects.
Below we also consider estimands defined as above except they condition on X and/or W; for
example risk(Z)(s1, s0, x, w) ≡ Pr(Y (Z) = 1 | S(1) = s1, S(0) = s0, X = x, W = w) and
CEPrisk(s1, s0, x, w) ≡ h(risk(1)(s1, s0, x, w), risk(0)(s1, s0, x, w)). The conditional estimands
reflect baseline covariatespecific surrogate value.
4. Estimating the CEP Surface and Marginal CEP Curve
We consider one approach to identifying and estimating the CEP surface in the practically
important special case CB. The same approach identifies and estimates the marginal CEP curve
in the general case that Si(0) has arbitrary variability. In case CB it is difficult to evaluate a
statistical surrogate, because it is not possible to study the correlation of S with Y in arm Z = 0
subjects, and it is conceptually difficult to evaluate whether S fully mediates clinical treatment
effects (Chan et al., 2002).
4.1 Identifiability of the Causal Estimands
Due to missing potential outcomes the CEP surface and marginal CEP curve are not identified
without further assumptions. A1–A3 imply
demonstrating that risk(Z)(s1, s0, x, w) would be identified if we knew the potential outcomes
Si(Z) of subjects assigned the opposite treatment 1 − Z. Estimating the CEP surface will
therefore require a way to predict the missing potential biomarkers. This challenge is relatively
easy in case CB, for which risk(1)(s1, c, x, w) is identified by the observed data in arm Z = 1.
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However, A1–A3 do not identify risk(0)(s1, c, x, w), and the remaining task to identify the CEP
surface entails determining values Si(1) for arm Zi = 0 subjects.
4.2 Baseline Predictor Study Design and Likelihood
Our method of inference is based on one of the augmented vaccine trial designs proposed by
Follmann (2006), wherein a baseline covariate(s) W that is predictive of S(1) is measured in
subjects in both treatment arms. A model predicting S(1) from X and W fit from arm Z = 1
subjects is used to predict S(1) for arm Z = 0 subjects. The predictions are unbiased because
A1–A3 imply S(1) | Z = 1, X, W =d S(1) | Z = 0, X, W, where =d denotes equality in distribution.
We observe i.i.d. data Oi ≡ (Zi, Xi, V i, Y i, δi, δiWi, δiZiSi ), i = 1,…, n. Only subjects with Vi
= 1 contribute to the likelihood. Subjects with Ziδi = 1 contribute risk(1)(Si, c, Xi, Wi; β)Yi(1 −
risk(1)(Si, c, Xi, Wi; β))1−Yi , where risk(1)(·, c, ·, ·; β) is modeled as a function of unknown
parameters β. The likelihood contribution for subjects with (1 − Zi)δi = 1 is obtained by
integrating risk(0)(·, c, Xi, Wi; β) over the conditional cdf , of S(1) | X, W. The contribution
for subjects with δi = 0 is obtained by integrating risk(Zi)(·, c, Xi;β) over the conditional cdf of
S(1), W |X, which is , where FW | X is the conditional cdf of W | X. Thus, with
, the conditional likelihood is
, where
Because CEPrisk(·, c, X, W; β) depends on β but not ν, the ν are nuisance parameters. Although
profile likelihood is a natural approach to pursue, it is difficult to implement because the
likelihood integrates over , and FW|X. We use estimated likelihood (Pepe and Fleming,
1991), also called pseudolikelihood, wherein consistent estimates of ν are obtained based on
treatment arm 1 data, and then L(β,ν ^) is maximized in β. The bootstrap is used to estimate
standard errors for β ^. A re-sampling approach is used because there does not appear to be an
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analytical expression for the asymptotic variance of β ^ that accounts for the variations in ν ^,
and previously developed techniques for deriving the variance do not apply because they would
assume that all subjects have a non-zero probability that S(1) is observed (e.g., Pepe and
Fleming, 1991).
4.3 Models for Risk (z)(·, c, ·, ·) and 
The estimated likelihood approach can be used for a variety of structural models for
risk(z)(s1, c, x, w) and the nuisance parameters ν. Here we consider two types of models for
case CB. The first is fully parametric, where we assume  and FW|X have particular
parametric distributions, and S(1) is continuous subject to “limit of detection” left-censoring:
S(1) ≡ max(S*(1), c), where S*(1) has a continuous cdf with Pr(S*(1) ≤ c) > 0. We also assume
the risk functions have a generalized linear model form
for s1 ≥ c and some known link function g(·). For example, we might assume FW|X is normal
and , is censored normal, with left-censoring of values below c, and A4-P holds with
g equal to the standard normal cdf Ф. This set-up extends Follmann (2006) to account for
censoring. With h(x, y) = g−1(x) − g−1(y), A4-P then implies
Simple calculations yield EDE(x, w) = (β10 − β00) + (β11 − β01)L + (β12 − β02)T x + (β13 −
β03)Tw, AS(x,w) = |(β10 − β00) + (β11 − β01)U + (β12 − β02)T x+(β13 − β03)Tw| − |EDE × (x,
w)|, and EAEω=1(x, w) = (β10 − β00) + (β11 − β01)E[S(1)|S(1) > c, x, w] + (β12 − β02)T x +
(β13 − β03)Tw. For the case that g = Ф, Web Appendix C provides a proof, adapted from a proof
by Dean Follmann, that β is identified under the untestable imposed constraint that one of the
components of  equals the corresponding component of . Therefore
identifiability requires assuming the absence of one interaction, but otherwise if and how the
CEP curve varies with X and W can be evaluated. If no interactions between treatment and X
or W are assumed, then CEPrisk(s1, c; β) = (β10 − β00) + (β11 − β01)s1 is interpreted as the
covariate-adjusted CEP curve.
Secondly, we consider a nonparametric approach wherein S and W are treated as categorical
variables with J and K levels, which may be discretized versions of continuous measurements.
Here we assume the lowest category j = 1 corresponds to the constant c in case CB. With W
the only baseline covariate, nonparametric models are specified by νjk ≡ Pr(S(1) = j, W = k)
and
for j = 1,…, J; k = 1,…,K; and z = 0, 1. The parameters
 are constrained such that  for all z, j,
k and  for identifiability. Under model A4-NP, W has the same effect on risk for the
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two study arms. This no-interaction assumption identifies the model, and the expanded model
with  replaced with  is not identified (see Web Appendix C).
In the simulations we consider the CEP curve estimand CEPrisk(j, 1; β) = log(risk(1)(j, 1; β1j)/
risk(0)(j, 1; β0j)) based on average risks
. It follows that CEPrisk(j, 1; β) = log
(β1j/β0j ), AS = |log(β1J/ β0J )| − |log(β11/ β01)|,EDE = log(β11/β01), and
 with  and .
For both the parametric and nonparametric approaches, Web Appendix B describes consistent
estimators of ν and procedures for maximizing L(β,ν̂) in β.
4.4 Tests for Whether a Biomarker Has Any Surrogate Value
Because PAEω = 0.5 supports that S has no surrogate value, Wald tests for any surrogate value
can be based on the maximum estimated likelihood estimator (MELE)  minus 0.5 divided
by its bootstrap standard error. Similarly Wald tests of AS = 0 can be implemented based on
. For the nonparametric approach assuming model A4-NP, we also consider a test statistic
 divided by its bootstrap standard error, where
. This test evaluates H0 : CEPrisk(j, 1) = CE for all j versus the monotone
alternative that CEPrisk(j, 1) increases in j, similar to the Breslow–Day trend test (Breslow and
Day, 1980). The null and alternative hypotheses indicate that average causal sufficiency does
not and does hold, respectively.
5. Simulation Study
Based on data from the first preventive HIV vaccine efficacy trial (Gilbert et al., 2005), we
conducted a simulation study to evaluate performance of the MELE methods. The vaccine trial
was double blind with 2:1 randomization to vaccine:placebo. A biomarker of interest S was
the 50% neutralization titers against the HIV recombinant gp120 molecule measured from a
serum sample drawn at the month 1.5 visit, and Y was HIV infection during the time period
t0 = 1.5 months to 36 months. The lower quantification limit of the neutralization assay was
1.65, and 44 of 47 placebo recipients with S measured at 1.5 months had left-censored values;
thus the data essentially fit case CB. The range of Si was [1.65, 4.09], which we rescaled to [0,
1], so that c = L = 0.
We simulated vaccine trials with the following steps. Step 1: For all 3598 (1805) subjects in
the vaccine (placebo) arm, (Wi, Si(1)) was generated from a bivariate normal distribution with
means 0.41, standard deviation 0.55, and correlation ρ = 0.5, 0.7, or 0.9; the standard deviation
was chosen such that 23% of Si(1) values were less than 0 on average. Simulated values of
Si(1) and W less than 0 (greater than 1) were set equal to 0 (1). Step 2: The Wi and Si(1) were
binned into quartiles. For subjects i with quartile j value of Si(1) and quartile k value of Wi,
Y i(Z) was generated from a Bernoulli distribution with success probability determined by
model A4-NP with values of βzj and  set as follows. First, the βzj were set to achieve the
infection rate Pr(Y (1) = 1) = 0.067 that was observed in the vaccine arm of the trial, an overall
vaccine efficacy of 50% (i.e., Pr(Y (0) = 1) = 2 × Pr(Y (1) = 1)) and to reflect a biomarker with
either (i) no or (ii) high surrogate value. Based on risk averaged over W described in Section
4.3, in scenario (i) CEPrisk(j, 1; β) ≡ log (risk(1)(j, 1; β1j)/risk(0)(j, 1; β0j)) = −0.69 for j = 1,…,
4 and in scenario (ii) CEPrisk(j, 1; β) = − 0.22, −0.51, −0.92, −1.61 for j = 1,…, 4. With vaccine
efficacy VE(j, 1) ≡ 1 − exp(CEPrisk(j, 1; β)), scenario (i) specifies constant VE(j, 1) = 0.5 and
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scenario (ii) specifies VE(j, 1) = 0.2, 0.4, 0.6, 0.8 for j = 1,…, 4. For both scenarios (i) and (ii),
we let  for k = 1, …, 4. Step 3: To achieve case–cohort sampling, (Wi,
Si(1)) was retained for all infected vaccine recipients and a subcohort of uninfected vaccine
recipients. For the placebo arm Si(1) was set to missing for everyone and Wi was retained only
for all infected placebo recipients and for a subcohort of uninfected placebo recipients. For
each arm, the ratio of controls to cases was 3:1. The simulated data sets satisfied A1–A3 and
A4-NP.
For each of 1000 simulated data sets the MELE β̂ was computed using the nonparametric
approach described in Section 4.3. Then, with h(x, y) = log(x/y), β̂ was used to compute the
MELEs of CEPrisk(j; 1), AS, and PAEω for ω(j; 1) = 1, j, and I(j = J = 4). Wald tests (with
bootstrap standard errors) based on  − 0.5, , and T were used to test for any surrogate
value. The MELEs of CEPrisk(j; 1), PAEω and AS performed well (Table 1 and Table 2).
Bootstrap percentile confidence intervals (CIs) had approximately nominal coverage and for
higher values of ρ the MELEs exhibited negligible bias. The tests for any surrogate value had
approximately nominal size and showed adequate power to detect surrogate value; the
nonparametric trend test had power 0.83, 0.99, and >0.99 for ρ = 0.5, 0.7, and 0.9 under scenario
(ii).
Additional simulations were conducted to evaluate the performance of the MELE method with
binned covariates when the data were generated from a continuous model. Specifically, Step
2 described above was replaced with Step 2′: For vaccine arm subjects, Y i(1) was generated
using model A4-P with g = Ф and (β10, β11, β12, β13) = (−1.21, −0.67, 0, −0.1) set to fit the
real vaccine arm data with infection rate 0.067. For the placebo arm, we supposed overall
vaccine efficacy of 50% and generated Y i(0) assuming model A4-P with β02 = 0, β03 = β13
and either (i) β01 = β11 or (ii) β01 = 0. For h(x, y) = g−1(x) − g−1(y), under (i) CEPrisk(s1, c; β)
= β10 − β00 = −1.21 − (−1.1) = −0.11 is constant, so that S has no surrogate value (with AS =
0 and PAEω = 0.5 for any weight function ω); under (ii) CEPrisk(s1, c; β) = −0.11 − 0.67 s1, so
that S has high surrogate value (with AS = 0.67 and PAEω = 0.88 for ω(j; 1) = I(j = J = 4)).
Using h(x, y) = g−1(x) − g−1(y), the MELEs and CIs of PAEω and AS performed well (Table
3). Relative to Table 2, there was a slight increase in bias and in standard errors. Tests for any
surrogate value had approximately nominal size, with power only slightly lower than in the
previous set of simulations. These simulation studies provide a “proof of principle” that the
proposed methods can reliably estimate the CEP surface and distinguish biomarkers with no
or high surrogate value.
6. Discussion
A main use of a surrogate endpoint is predicting treatment effects on a clinical endpoint. Within
the principal surrogate framework, we have introduced the CEP surface and the marginal CEP
curve as appropriate estimands for measuring the predictive capacity of a candidate surrogate.
We developed estimation and testing methods under case–cohort sampling from a single large
clinical trial (or multiple similar trials); such inferences apply for measuring surrogate
predictiveness for the same or similar setting as the trial. The inferences do not form an
empirical basis for bridging information about clinical efficacy to a new setting not represented
in the trial(s) (e.g., to a new human population or treatment formulation); for this additional
experiments (such as mechanistic studies and studies that deliberately manipulate the
biomarker) and metaanalysis of heterogeneous studies are needed.
Because the definition of the CEP surface involves unobservable potential outcomes, strong
untestable assumptions may be needed to identify it, possibly precluding its reliable estimation.
The estimation method we developed requires A1–A3, a reasonably good model predicting
S from baseline covariates X and W in treatment arm 1, and models for risk(z)(s1, c, x, w) or its
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marginal counterpart risk(z)(s1, x, w), for z = 0, 1. A1–A2 are standard in blinded randomized
trials. A1 (SUTVA) is potentially dubious in the infectious disease setting where dependent
happenings are possible (Halloran and Struchiner, 1995), but should approximately hold in
trials with a small study population relative to the total population of at risk individuals. A3
can be assessed by testing  at each of multiple
fixed baseline covariate levels x, where rejecting  for any x rejects A3. It is difficult to fully
verify A3, however, due to the curse of dimensionality. The method is expected to be robust
to violations of A3 if the vast majority of clinical events happen after the biomarker
measurement time. Otherwise it will be important to extend the methods to facilitate sensitivity
analyses to departures from A3.
Models for the conditional distribution of S given X and W can be directly checked using arm
Z = 1 data, and under A1–A3 models for risk(1)(s1, c, x, w) can be tested. The model for
risk(0)(s1, c, x, w) specified by A4-P or A4-NP is not testable. However, with extra data
collection Follmann’s (2006) “close-out placebo vaccination” approach would provide one
way to test it. Given the challenge in verifying this assumption, sensitivity analysis and the use
of multiple surrogate evaluation approaches is warranted.
Within the principal surrogate framework considered here, internal validity of the putative
surrogate can be checked by comparing the estimated overall clinical treatment effect,
, to the CE predicted from the biomarker. Under A1–A3 and
case CB, CE can be predicted by , which averages the
predicted clinical treatment effect over the distribution of observed marker values of subjects
assigned arm Z = 1. Furthermore, the estimated CEP curve can be used to check projective
validity, that is, the utility of S for bridging efficacy predictions across populations. For
example, suppose treatments Z = 1 and Z = 0 are compared within two subroups of a large trial.
The CEP surface can be estimated from subgroup 1 data, and Pred(CE) calculated by estimating
F(1)(·) from the observed biomarker values S of subgroup 2 subjects in arm Z = 1. Then
projective validity would be supported by Pred(CE) near  for subgroup 2.
The estimands and estimation techniques developed here for a binary clinical endpoint Y also
apply for a quantitative clinical endpoint Y, with all expressions Pr(Y (Z) = 1 | ·) replaced with
E(Y (Z) | ·). In either case the CEP estimands describe how the average or population level
causal effect on Y depends on the causal effect on S.
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Example CEPR(υ1, υ0) = h(R(1)( υ1, υ0), R(0)( υ1, υ0)) surfaces, with h(x, y) = 1 − x/y. The
surface in (i) reflects a biomarker with no surrogate value, wherein the clinical treatment effect
is the same for all treatment effects on the biomarker. The surface in (ii) reflects a biomarker
with high surrogate value, wherein the average causal effect on the clinical endpoint is zero
for υ1 = υ0 and has a large increase in υ1 − υ0 for υ1 > υ0. Because CEPR(υ1, υ0) = 0 for υ1 =
υ0, both biomarkers satisfy average causal necessity. Furthermore, because CEPR( υ1, υ0) > 0
for all υ1 > υ0, the biomarker in (ii) satisfies one-sided average causal sufficiency. This figure
appears in color in the electronic version of this article.
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For case CB with Si(0) = c for all i with c = L the lower bound of S, biomarkers S that have no
(horizontal solid line), modest (dashed line), moderate (dotted line), and high (hatched line)
surrogate value. Here CEPrisk(s1, c) = h(risk(1)(s1, c), risk(0)(s1, c)) with h(x, y) = 1 − x/y.
Because CEPrisk(c, c) = 0 and CEPrisk(s1, c) > 0 for all s1 > c, the latter two S’s satisfy average
causal necessity and average causal sufficiency, and hence are principal surrogates. This figure
appears in color in the electronic version of this article.
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